Literature DB >> 19570017

Insulin delivery through the ocular route.

R Srinivasan1, S K Jain.   

Abstract

The effect of insulin solution on the reduction of blood glucose concentration was studied after the administration of insulin solution through various routes-subcutaneous (SV), intravenous (IV), and ocular. Ocular administration of free insulin (400 U/mL) to normal rabbits produced no change in blood glucose level unless permeation enhancer was included in the dosing solution. Various concentrations of insulin were studied for their effectiveness on ocular administration and 10 U/kg dose was found to be optimum for ocular instillation. Among various penetration enhancers, poIyoxyethylene-9-lauryl ether (POE) in 0.8% w/w concentration exhibited better ocular compatibility and penetration-enhancing effect. The effectiveness of liposomes in aiding ocular absorption of entrapped insulin was studied in normal rabbits. Administration of insulin entrapped in positively charged liposomes composed of egg phosphatidylcholine with cholesterol and stearylamine (10: 2:1, in weight ratio) to normal rabbits produced substantial reduction in blood glucose concentration 90-120 min after the instillation of the formulation. In conclusion, it seems that administration of insulin in liposomes not only promotes the ocular absorption, but also controls and prolongs the drug action.

Entities:  

Year:  1998        PMID: 19570017     DOI: 10.3109/10717549809052027

Source DB:  PubMed          Journal:  Drug Deliv        ISSN: 1071-7544            Impact factor:   6.419


  2 in total

Review 1.  Routes for the delivery of insulin to the central nervous system: A comparative review.

Authors:  Elizabeth M Rhea; Therese S Salameh; William A Banks
Journal:  Exp Neurol       Date:  2018-11-27       Impact factor: 5.330

2.  Formulation development, in vitro and in vivo evaluation of chitosan engineered nanoparticles for ocular delivery of insulin.

Authors:  Priyanka Rathore; Alok Mahor; Surendra Jain; Anzarul Haque; Prashant Kesharwani
Journal:  RSC Adv       Date:  2020-12-08       Impact factor: 4.036

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.